MGI Tech Co., Ltd. (MGI), a global innovator in life science technologies, and JCBio Co., Ltd. (JCBio), a leading South Korean biotechnology company, have signed a Memorandum of Understanding (MoU) to launch the DCS Lab Project—a groundbreaking collaboration set to accelerate multi-omics research, novel sequencing applications, precision medicine, clinical translation, and AI-driven data insights in South Korea.
This partnership integrates MGI’s proprietary short-read and long-read sequencing technologies with JCBio’s local expertise, equipping laboratories with end-to-end multi-omics capabilities. The collaboration aims to empower researchers and clinicians to address complex biological challenges with greater accuracy, while reinforcing South Korea’s role as a regional leader in genomics and biotechnology.
Through the DCS Lab Project, JCBio will deploy advanced sequencing strategies, enhance integrated multi-omics analysis, and advance innovations in precision medicine and clinical translation. This positions JCBio as a local hub for cutting-edge genomic and omics-driven research.
Launched in 2023, MGI’s DCS Lab Initiative (DNA genomics, Cell omics, Spatial omics) was designed to empower global laboratories with comprehensive sequencing solutions. It is the industry’s first global program offering end-to-end platforms across DNA, cell, and spatial omics, driving frontier science across multiple disciplines.
The initiative has already enabled pioneering breakthroughs worldwide. At MGI’s Customer Experience Centre (CEC) in Australia, solutions such as DNBelab-C4 (single-cell omics) and STOmics Stereo-seq (spatial transcriptomics) have advanced cancer research, medicine, and agriculture. Extending this success, the collaboration with JCBio brings the initiative to South Korea, marking a new milestone in Asia’s rapidly growing biotech ecosystem.
"We are excited to partner with JCBio, an organization that shares our commitment to scientific excellence and innovation," said Dr. Roy Tan, Director of MGI Northeast Asia. "With the DCS Lab Project, we are not only deploying sequencing platforms but establishing a hub for multi-omics discovery that equips South Korea's research community with the tools to drive frontier science and improve human health."
"This partnership with MGI is a game-changer for South Korea's research community," added JaeChan Yoo, CEO of JCBio."By integrating long- and short-read sequencing technologies, the DCS Lab enables researchers to tackle complex biological questions and accelerate breakthroughs in precision medicine and multi-omics research. Together, we are supporting South Korea's growing role in global genomics research."